Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Jacobs

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Frontiers in Physiology|January 21, 2025
The effects of aerobic exercise and heat stress on the unbound fraction of caffeineMackenzie McLaughlin, Kaye Dizon, Ira Jacobs
Journal of Sports Sciences|April 8, 2025
No ergogenic effect of ischemic preconditioning applied 5 or 30 min before maximal self-paced cycling exerciseAlex Isidori, Liam O'Brien, Ira Jacobs
Journal of Dietary Supplements|May 20, 2021
The Effects of L-Citrulline on Blood-Lactate Removal Kinetics Following Maximal-Effort ExerciseBenjamin Divito, Mackenzie McLaughlin, Ira Jacobs
Medicine and Science in Sports and Exercise|June 5, 2003
Effects of ephedrine, caffeine, and their combination on muscular enduranceIra Jacobs, Harley Pasternak, Douglas G Bell
Aviation, Space, and Environmental Medicine|June 20, 2006
Physical conditioning to enhance +Gz tolerance: issues and current understandingWilliam A Bateman, Ira Jacobs, Fred Buick
Cancer Management and Research|May 9, 2017
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscapeJanakiraman Subramanian, Jamie Cavenagh, Bhardwaj Desai, et al.
Biologics : Targets & Therapy|March 4, 2017
Biosimilars and the extrapolation of indications for inflammatory conditionsJohn Rp Tesser, Daniel E Furst, Ira Jacobs
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 13, 2017
Biosimilars for the Treatment of Cancer: A Systematic Review of Published EvidenceIra Jacobs, Reginald Ewesuedo, Sadiq Lula, et al.
Pharmaceuticals (Basel, Switzerland)|May 10, 2014
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician SurveyWilliam H Baer Ii, Archana Maini, Ira Jacobs
Pharmaceuticals (Basel, Switzerland)|September 19, 2014
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging MarketsPhilip Lammers, Carmen Criscitiello, Giuseppe Curigliano, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Physiology|January 21, 2025
The effects of aerobic exercise and heat stress on the unbound fraction of caffeineMackenzie McLaughlin, Kaye Dizon, Ira Jacobs
Journal of Sports Sciences|April 8, 2025
No ergogenic effect of ischemic preconditioning applied 5 or 30 min before maximal self-paced cycling exerciseAlex Isidori, Liam O'Brien, Ira Jacobs
Journal of Dietary Supplements|May 20, 2021
The Effects of L-Citrulline on Blood-Lactate Removal Kinetics Following Maximal-Effort ExerciseBenjamin Divito, Mackenzie McLaughlin, Ira Jacobs
Medicine and Science in Sports and Exercise|June 5, 2003
Effects of ephedrine, caffeine, and their combination on muscular enduranceIra Jacobs, Harley Pasternak, Douglas G Bell
Aviation, Space, and Environmental Medicine|June 20, 2006
Physical conditioning to enhance +Gz tolerance: issues and current understandingWilliam A Bateman, Ira Jacobs, Fred Buick
Cancer Management and Research|May 9, 2017
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscapeJanakiraman Subramanian, Jamie Cavenagh, Bhardwaj Desai, et al.
Biologics : Targets & Therapy|March 4, 2017
Biosimilars and the extrapolation of indications for inflammatory conditionsJohn Rp Tesser, Daniel E Furst, Ira Jacobs
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 13, 2017
Biosimilars for the Treatment of Cancer: A Systematic Review of Published EvidenceIra Jacobs, Reginald Ewesuedo, Sadiq Lula, et al.
Pharmaceuticals (Basel, Switzerland)|May 10, 2014
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician SurveyWilliam H Baer Ii, Archana Maini, Ira Jacobs
Pharmaceuticals (Basel, Switzerland)|September 19, 2014
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging MarketsPhilip Lammers, Carmen Criscitiello, Giuseppe Curigliano, et al.
Pageof 9